短乳杆菌SLB1000对Ⅱ型糖尿病大鼠的控糖作用  

Glucose Control Effect of Lactobacillus brevis SLB1000 on Type Ⅱ Diabetes Rats

作　　者：杜静婷 蔺楠 施俊凤 DU Jingting;LIN Nan;SHI Junfeng(College of Food Science and Engineering,Shanxi Agricultural University,Taiyuan 030031,China)

机构地区：[1]山西农业大学食品科学与工程学院,山西太原030031

出　　处：《保鲜与加工》2024年第2期56-61,共6页Storage and Process

基　　金：山西省重点研发计划项目(202102140601017);山西省现代农业产业技术体系(果树)建设专项资金(SXFRS-2022)。

摘　　要：为探索更为安全无副作用的控糖方法,对实验室筛选所得的一株短乳杆菌(Lactobacillus brevis)SLB1000进行体内试验,观察其可能具有的益生效果,以期为益生菌的研究和利用提供依据。以SD大鼠为试验对象,构建Ⅱ型糖尿病模型大鼠。灌胃不同剂量(1×10^(8) CFU/mL和1×10^(10) CFU/mL)的短乳杆菌SLB1000,定期测定大鼠的体重、空腹血糖、口服葡萄糖耐量(OGTT),于试验第75天解剖,测定大鼠脏器指数、血清和肝脏中抗氧化相关酶活性。结果表明,短乳杆菌SLB1000延缓了Ⅱ型糖尿病引起的大鼠体重下降,可降低空腹血糖,且呈剂量依赖关系。与模型组对比,高剂量组(1×10^(10) CFU/mL)可抑制体重下降12.82%,使空腹血糖降低67.21%,达到6.43 mmol/L,肾脏指数和肝脏指数分别降低了20.95%和27.62%,效果好于二甲双胍,有效缓解脏器肥大。短乳杆菌SLB1000还可提高体内超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)和过氧化氢酶(CAT)的活性,有效降低Ⅱ型糖尿病大鼠的血糖水平,显著提高葡萄糖耐受性及抗氧化能力,可见该菌株具有较好的开发潜力。In order to explore a safer sugar control method without side effects,a strain of Lactobacillus brevis SLB1000 screened in the laboratory was tested in vivo to observe its possible probiotic effects,so as to provide a basis for the research and utilization of probiotics.SD rats were used to construct type Ⅱ diabetes model rats.Different doses of SLB1000(1×10^(8) CFU/mL,1×10^(10) CFU/mL)were gavaged,and the body weight,fasting blood glucose and oral glucose tolerance(OGTT)of rats were measured regularly.On the 75th day of the experiment,the rats were dissected,the organ index,the activity of antioxidant enzymes in serum and liver of rats were measured.The results showed that Lactobacillus brevis SLB1000 delayed the type Ⅱ diabetes-induced weight loss of rats,and reduced fasting blood glucose in a dose-dependent manner.Compared with the model group,the high-dose group(1×10^(10) CFU/mL)could inhibit weight loss by 12.82%,reduce fasting blood glucose by 67.21%,reach to 6.43 mmol/L,and reduce kidney and liver indices by 20.95% and 27.62%,respectively,which was better than metformin and effectively alleviated organ hypertrophy.Lactobacillus brevis SLB1000 could also increase the activities of superoxide dismutase(SOD),glutathione peroxidase(GSH-Px)and catalase(CAT)in the body,effectively reduce the blood sugar level of type Ⅱ diabetes rats,significantly improve glucose tolerance and antioxidant capacity.Which suggests that the strain has good development potential.

关 键 词：短乳杆菌SLB1000 控糖作用 SD大鼠 抗氧化 

分 类 号：TS201.3[轻工技术与工程—食品科学]